Clinical Trials Logo

Clinical Trial Summary

By carrying a careful, large-scale and ambitious prospective study of a cohort of participants with generalized epilepsy, the study team hopes to clarify the likelihood of response and remission in this type of epilepsy, and try to explore the underlying biological drivers of treatment response, including novel realms of exploration such as impact of the microbiome, and genetics. The identification of biomarkers that predict the likelihood of disease response would allow epilepsy patients to make more informed decisions about the factors affecting their quality of life, including plans for driving, relationships, pregnancy, schooling, work, and play. In addition to its impact on clinical care, the data and specimens collected in HEP3, including sequential electrophysiology, biochemical profiles and neuroimaging and banked DNA for future genomics studies, have the potential to provide new insights into the biological basis of IGE, thereby advancing the discovery of effective treatments and cures. By enrolling both newly diagnosed subjects (prognosis unknown) as well as subjects with established IGE who are already determined to be treatment resistant or treatment responsive, the study team can immediately test potential biomarkers in a confirmation cohort, which will accelerate identification of predictive biomarkers.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05374928
Study type Observational
Source NYU Langone Health
Contact Jacqueline French, MD
Phone 646-558-0839
Email Jacqueline.French@nyulangone.org
Status Recruiting
Phase
Start date March 9, 2020
Completion date June 2025

See also
  Status Clinical Trial Phase
Completed NCT01432821 - Blinking and Yawning in Epilepsy: The Role of Dopamine N/A
Completed NCT04252846 - A Study to Investigate Dosage, Effectiveness, and Safety of Perampanel When Used as First Add-on Therapy in Participants >=12 Years With Partial Onset Seizures With or Without Secondary Generalization or With Primary Generalized Tonic-Clonic Seizures Associated With Idiopathic Generalized Epilepsy
Active, not recruiting NCT05147571 - RNS System NAUTILUS Study Phase 3
Recruiting NCT05530109 - Study of Attentional Disorders in Patients Suffering From Idiopathic Generalized Epilepsy.